Notably, KIR-only NK cells hold substantial promise for adoptive NK cell therapy since they have the potential to eradicate allogeneic tumor cells based on their expression of licensed KIR that can be deliberately mismatched against a patient’s HLA class I type (18). This evidence concerns the gene KIR3DL1 and neoplasm.